Table 5.
Multivariate analysis for overall survival.
| Hazard ratio | 95% CI (Lower) | 95% CI (Upper) | p-value | |
|---|---|---|---|---|
| Age at diagnosis, n | ||||
| <40 y | 1 | |||
| 40–64 y | 1.733 | 0.788 | 3.813 | 0.171 |
| >64 y | 2.152 | 0.914 | 5.068 | 0.080 |
| Extent of surgical resection, n | ||||
| Gross total resection | 1 | |||
| Subtotal resection | 1.917 | 1.216 | 3.024 | 0.005 |
| Biopsy | 1.253 | 0.828 | 1.897 | 0.285 |
| Comorbidities at diagnosis, n | ||||
| Diabetes Mellitus | 1.215 | 0.832 | 1.774 | 0.314 |
| Hypertension | 0.767 | 0.550 | 1.069 | 0.117 |
| Ischemic heart disease | 3.236 | 1.553 | 6.744 | 0.002 |
| RT total dose (Gy), n | ||||
| ≥56 | 1 | |||
| 36–50 | 1.106 | 0.558 | 2.193 | 0.772 |
| ≤32 | 3.336 | 1.236 | 9.000 | 0.017 |
| No. of adjuvant Temozolomide cycles*, n | ||||
| 0 | 1 | |||
| 1–3 | 1.131 | 0.515 | 2.484 | 0.759 |
| 4–6 | 1.093 | 0.503 | 2.374 | 0.823 |
| 7–9 | 0.541 | 0.221 | 1.323 | 0.178 |
| ≥10 | 0.206 | 0.092 | 0.464 | 0.000 |
| Patients who switched to 2nd line therapy | ||||
| Yes | 1 | |||
| No | 0.494 | 0.351 | 0.695 | 0.000 |
| Waiting time until concomitant therapy with RT + TMZ, d | ||||
| <28 days | 1 | |||
| 28–42 days | 0.867 | 0.561 | 1.339 | 0.520 |
| ≥42 days | 0.498 | 0.319 | 0.777 | 0.002 |
| *Post concomitant therapy with RT + TMZ. | ||||
Hazard ratio (HR) less than 1 – better overall survival, > 1 – worse overall survival; P-value < 0.05 – statistically significant.